Calidi Biotherapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2022 | — | $-50.4M | $590.0K |
| FY2023 | $2.1M | $-8.2M | $2.2M |
| FY2024 | $600.0K | $1.5M | $9.6M |
| FY2025 | $600.0K | $3.8M | $5.8M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2022 | — | $-50.4M | $590.0K |
| FY2023 | $2.1M | $-8.2M | $2.2M |
| FY2024 | $600.0K | $1.5M | $9.6M |
| FY2025 | $600.0K | $3.8M | $5.8M |